Fig. 1

Validation of TET2 mutation in NCI-H23 cells by Sanger sequencing, and frequency of TET2 and/or DNMT3A mutations in human malignancies: a TET2 c.5162T > G missense mutation (upper panel; arrow) in NCI-H23 cells versus no alteration at the site in HCT116 cells (lower panel). Shown were all forward strands. b Frequency of TET2 and/or DNMT3A mutations in human malignancies analyzed from cBioPortal. AML, acute myeloid leukemia; CEBPA, CCAAT/enhancer-binding protein alpha; NPM, nucleophosmin; NSCLC, non-small cell lung cancer; NOS, not otherwise specified